STIM Neuronetics, Inc.
8-K Current Report
Filed: March 17, 2026
Health Care
Surgical & Medical Instruments & ApparatusNeuronetics, Inc. (STIM) 8-K current report filed with SEC EDGAR on March 17, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items3 items
- Item 2.02: Results of Operations and Financial Condition
- Item 5.02: Departure/Election of Directors or Officers
- Item 7.01: Regulation FD Disclosure
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 earnings released March 17, 2026 — covering period ended December 31, 2025
- • Full financial details in Exhibit 99.1 press release; key figures not disclosed in this filing item
Item 5.02 · Departure/Election of Directors or Officers
- • New CEO Daniel Reuvers starts March 23, 2026; age 63 with 35+ years medtech experience including CEO of Tactile Medical (TCMD) 2020–2024
- • Base salary $730,000 with target annual bonus at 100% of base salary (~$730,000 target total cash)
Item 7.01 · Regulation FD Disclosure
- • Forward-looking statements cover revenue, expenses, growth outlook for upcoming quarters and full-year fiscal 2026
- • Key risk flags: reliance on NeuroStar system for all revenue, history of losses, ability to maintain positive cash flow
Other Neuronetics, Inc. 8-K Filings
Get deeper insights on Neuronetics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.